Key facts: Q3 beat; Novartis deal expands; analysts lift target

What happened

Schrödinger reported third-quarter revenue of $64.49 million, up 18.7% from a year earlier and above estimates, while hosted software revenue rose 49% and its adjusted loss was $0.50 per share. It also amended its Novartis agreement, replacing existing programs with two new ones and raising potential milestone payments to $1.424 billion.

Confirmed

Global impact / market context

Higher software revenue could strengthen Schrödinger’s recurring business, while the expanded Novartis agreement offers potential future payments tied to program progress. However, milestone payments are not guaranteed revenue, and the reported adjusted loss means investors still need evidence that growth can translate into improved profitability.

Analyst inference

The article presents mixed signals: revenue exceeded estimates and Bristol Myers Squibb adopted Schrödinger’s Bunsen platform, but the company reported an adjusted loss. Analysts raised their average 12-month target to $27.29 from $25.86, yet it still implied about 4% downside.

Confirmed

What to watch

1. Check later reports for revenue growth and adjusted losses, especially whether hosted software continues expanding and whether the company shows progress toward turning sales growth into better financial results. Analyst inference
2. Track updates on the amended Novartis programs and any milestone payments; the $1.424 billion figure is potential payments, not an amount the article says Schrödinger has received. Confirmed
3. Watch whether Bristol Myers Squibb’s adoption of Bunsen leads to broader platform use, and whether the article’s stated early access and expected full release by year-end proceed as planned. Analyst inference

Evidence

• Original source link unavailable